Share Price and Basic Stock Data
Last Updated: November 17, 2025, 8:40 pm
| PEG Ratio | 0.53 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dishman Carbogen Amcis Ltd operates within the pharmaceuticals sector, focusing on contract research and manufacturing services. As of October 2023, the company reported a market capitalization of ₹4,629 Cr and a stock price of ₹295. The revenue from operations for the trailing twelve months (TTM) stood at ₹2,896 Cr, reflecting a steady increase from ₹2,413 Cr in March 2023 and ₹2,141 Cr in March 2022. The company has demonstrated resilience in its sales performance, with quarterly revenues peaking at ₹789 Cr in September 2024. However, there was a decline in revenue to ₹524 Cr in June 2024, indicating volatility in operational performance. Overall, the sales trajectory suggests a compound growth rate, although fluctuations in quarterly figures highlight the need for consistent demand stability in the pharmaceutical sector.
Profitability and Efficiency Metrics
Dishman Carbogen Amcis Ltd’s profitability metrics reveal a complex landscape. The operating profit margin (OPM) recorded a peak of 21% in December 2024 but faced significant fluctuations throughout the reporting periods, with a low of 6% in June 2024. The net profit for the TTM stood at ₹104 Cr, a recovery from a net loss of ₹30 Cr in March 2023 and a further decline to a loss of ₹153 Cr in March 2024. The company’s return on equity (ROE) was reported at 0.32%, while the return on capital employed (ROCE) was notably low at 2.42%. The interest coverage ratio (ICR) of 3.08x suggests that the company’s earnings are sufficient to cover its interest obligations, although it remains a modest figure compared to industry standards, indicating potential concerns regarding operational efficiency and profitability sustainability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dishman Carbogen Amcis Ltd displays a mixed financial health profile. As of March 2025, the company’s total borrowings were ₹2,389 Cr against reserves of ₹5,800 Cr, highlighting a prudent leverage position with a debt-to-equity ratio of 0.35. The current ratio stood at 1.14, indicating adequate liquidity to cover short-term liabilities. However, the cash conversion cycle (CCC) of 577 days is significantly longer than typical sector averages, which can stress operational cash flows. The price-to-book value (P/BV) ratio was recorded at 0.58x, suggesting that the stock is undervalued compared to its book value, potentially indicating investment appeal. Nonetheless, the low return on assets (ROA) of 0.03% raises concerns about asset utilization efficiency, warranting closer scrutiny by investors.
Shareholding Pattern and Investor Confidence
Dishman Carbogen Amcis Ltd’s shareholding pattern reflects a stable yet cautious investor sentiment. Promoters hold a substantial 59.32% stake, indicating strong control and commitment to the company’s long-term vision. Foreign institutional investors (FIIs) accounted for 9.94%, showing a slight increase from 8.80% in September 2023, while domestic institutional investors (DIIs) maintained a modest 1.27% stake. The public shareholding stood at 29.48%, which indicates a diverse investor base. The total number of shareholders decreased to 49,744 as of June 2025, reflecting a potential consolidation of ownership. This pattern can be interpreted as a sign of investor confidence, although the decline in shareholder numbers may raise questions regarding liquidity and market interest in the stock.
Outlook, Risks, and Final Insight
Looking ahead, Dishman Carbogen Amcis Ltd faces both opportunities and risks. Strengths include its significant promoter backing, a diversified revenue stream, and improving net profit figures, which could enhance market positioning. However, risks such as the high cash conversion cycle, fluctuating profitability margins, and low ROCE may hinder growth prospects. Additionally, the pharmaceutical industry’s regulatory challenges and competition could affect operational stability. To navigate these challenges, the company may need to optimize its operational efficiency and strengthen its market presence. Should the company successfully address these operational challenges and stabilize its revenue streams, it may enhance shareholder value significantly over time.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dishman Carbogen Amcis Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 126 | 247/84.3 | 35.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,871 Cr. | 447 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.6 Cr. | 26.4 | 29.1/17.0 | 91.9 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,388.14 Cr | 1,192.94 | 53.66 | 202.20 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 541 | 614 | 640 | 619 | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 |
| Expenses | 452 | 535 | 526 | 567 | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 |
| Operating Profit | 88 | 79 | 114 | 51 | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 |
| OPM % | 16% | 13% | 18% | 8% | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% |
| Other Income | 6 | 9 | 4 | -39 | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 |
| Interest | 19 | 20 | 22 | 24 | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 |
| Depreciation | 75 | 80 | 50 | 76 | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 |
| Profit before tax | -0 | -12 | 46 | -88 | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 |
| Tax % | -1,437% | -18% | -3% | -19% | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% |
| Net Profit | 4 | -10 | 47 | -71 | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 |
| EPS in Rs | 0.26 | -0.64 | 3.00 | -4.51 | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 |
Last Updated: August 20, 2025, 11:35 am
Below is a detailed analysis of the quarterly data for Dishman Carbogen Amcis Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 708.00 Cr.. The value appears to be declining and may need further review. It has decreased from 716.00 Cr. (Mar 2025) to 708.00 Cr., marking a decrease of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 567.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 564.00 Cr. (Mar 2025) to 567.00 Cr., marking an increase of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 141.00 Cr.. The value appears to be declining and may need further review. It has decreased from 153.00 Cr. (Mar 2025) to 141.00 Cr., marking a decrease of 12.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 20.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from -4.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 26.00 Cr..
- For Interest, as of Jun 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 42.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 81.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 81.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 11.00 Cr..
- For Tax %, as of Jun 2025, the value is 39.00%. The value appears to be increasing, which may not be favorable. It has increased from -56.00% (Mar 2025) to 39.00%, marking an increase of 95.00%.
- For Net Profit, as of Jun 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 43.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 20.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.49. The value appears to be declining and may need further review. It has decreased from 2.75 (Mar 2025) to 1.49, marking a decrease of 1.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:28 am
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,759 |
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,177 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 582 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 17% | 21% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 34 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 176 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 317 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 124 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | 83% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 136 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 8.70 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.90% | 35.48% | -24.29% | -203.77% | 110.91% | -266.67% | -410.00% | 101.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | 28.59% | -59.77% | -179.49% | 314.68% | -377.58% | -143.33% | 511.96% |
Dishman Carbogen Amcis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 150% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 31% |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:05 am
Balance Sheet
Last Updated: November 9, 2025, 1:55 pm
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 0.00 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 863 | 4,814 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 | 5,596 | 5,800 | 6,334 |
| Borrowings | 868 | 950 | 1,095 | 1,042 | 1,357 | 1,589 | 1,830 | 2,209 | 2,313 | 2,389 | 2,559 |
| Other Liabilities | 334 | 811 | 967 | 899 | 1,121 | 1,068 | 1,255 | 1,421 | 1,631 | 1,766 | 2,185 |
| Total Liabilities | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,109 |
| Fixed Assets | 1,012 | 4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,188 | 6,724 | 7,055 | 7,954 |
| CWIP | 307 | 133 | 151 | 175 | 234 | 486 | 780 | 1,043 | 646 | 467 | 309 |
| Investments | 1 | 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 | 97 | 91 |
| Other Assets | 761 | 1,550 | 1,757 | 1,881 | 2,091 | 2,000 | 1,758 | 1,959 | 2,098 | 2,368 | 2,756 |
| Total Assets | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,109 |
Below is a detailed analysis of the balance sheet data for Dishman Carbogen Amcis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 6,334.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,800.00 Cr. (Mar 2025) to 6,334.00 Cr., marking an increase of 534.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,559.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,389.00 Cr. (Mar 2025) to 2,559.00 Cr., marking an increase of 170.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,185.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,766.00 Cr. (Mar 2025) to 2,185.00 Cr., marking an increase of 419.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 11,109.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,987.00 Cr. (Mar 2025) to 11,109.00 Cr., marking an increase of 1,122.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,954.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,055.00 Cr. (Mar 2025) to 7,954.00 Cr., marking an increase of 899.00 Cr..
- For CWIP, as of Sep 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 467.00 Cr. (Mar 2025) to 309.00 Cr., marking a decrease of 158.00 Cr..
- For Investments, as of Sep 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,756.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,368.00 Cr. (Mar 2025) to 2,756.00 Cr., marking an increase of 388.00 Cr..
- For Total Assets, as of Sep 2025, the value is 11,109.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,987.00 Cr. (Mar 2025) to 11,109.00 Cr., marking an increase of 1,122.00 Cr..
Notably, the Reserves (6,334.00 Cr.) exceed the Borrowings (2,559.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -667.00 | -498.00 | 444.00 | 551.00 | 502.00 | 273.00 | 330.00 | 330.00 | 284.00 | 467.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 61 | 96 | 79 | 103 | 80 | 81 | 89 | 68 | 90 |
| Inventory Days | 272 | 473 | 525 | 496 | 462 | 402 | 526 | 568 | 540 | 655 |
| Days Payable | 172 | 95 | 201 | 176 | 226 | 132 | 158 | 155 | 149 | 168 |
| Cash Conversion Cycle | 160 | 439 | 419 | 399 | 340 | 350 | 449 | 502 | 458 | 577 |
| Working Capital Days | -52 | 35 | 44 | 43 | -10 | -2 | -8 | -37 | -148 | -35 |
| ROCE % | 5% | 6% | 4% | 0% | 1% | 1% | 0% | 2% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Flexi Cap Fund | 2,377,050 | 0.96 | 33.73 | 2,377,050 | 2025-04-22 17:25:37 | 0% |
| L&T Flexicap Fund - Regular Plan | 2,377,050 | 0.81 | 23.47 | 2,377,050 | 2025-04-22 17:25:37 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 63,747 | 0.2 | 0.9 | 63,747 | 2025-04-22 17:25:37 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 681 | 0.12 | 0.01 | 681 | 2025-04-22 17:25:37 | 0% |
| Groww Nifty Total Market Index Fund | 149 | 0.01 | 0 | 149 | 2025-04-22 17:25:37 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 0.21 | -9.79 | -1.90 | 1.15 | -10.53 |
| Diluted EPS (Rs.) | 0.21 | -9.79 | -1.90 | 1.15 | -10.53 |
| Cash EPS (Rs.) | 18.94 | 10.04 | 16.00 | 20.77 | 9.11 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 371.91 | 358.90 | 370.51 | 353.89 | 363.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 371.91 | 358.90 | 370.51 | 353.89 | 363.44 |
| Revenue From Operations / Share (Rs.) | 172.93 | 166.82 | 153.89 | 136.52 | 121.94 |
| PBDIT / Share (Rs.) | 31.29 | 20.07 | 22.96 | 23.90 | 19.95 |
| PBIT / Share (Rs.) | 12.56 | 0.24 | 5.05 | 4.29 | 0.30 |
| PBT / Share (Rs.) | 1.23 | -7.80 | -3.48 | -0.27 | -4.15 |
| Net Profit / Share (Rs.) | 0.20 | -9.79 | -1.90 | 1.15 | -10.53 |
| NP After MI And SOA / Share (Rs.) | 0.20 | -9.79 | -1.90 | 1.15 | -10.53 |
| PBDIT Margin (%) | 18.09 | 12.03 | 14.91 | 17.50 | 16.35 |
| PBIT Margin (%) | 7.26 | 0.14 | 3.28 | 3.13 | 0.25 |
| PBT Margin (%) | 0.71 | -4.67 | -2.26 | -0.19 | -3.40 |
| Net Profit Margin (%) | 0.11 | -5.86 | -1.23 | 0.84 | -8.63 |
| NP After MI And SOA Margin (%) | 0.11 | -5.86 | -1.23 | 0.84 | -8.63 |
| Return on Networth / Equity (%) | 0.05 | -2.72 | -0.51 | 0.32 | -2.89 |
| Return on Capital Employeed (%) | 2.43 | 0.05 | 1.03 | 0.93 | 0.06 |
| Return On Assets (%) | 0.03 | -1.60 | -0.31 | 0.20 | -1.98 |
| Long Term Debt / Equity (X) | 0.19 | 0.04 | 0.18 | 0.13 | 0.08 |
| Total Debt / Equity (X) | 0.35 | 0.34 | 0.31 | 0.25 | 0.18 |
| Asset Turnover Ratio (%) | 0.27 | 0.27 | 0.26 | 0.04 | 0.03 |
| Current Ratio (X) | 1.14 | 0.75 | 1.07 | 1.29 | 1.33 |
| Quick Ratio (X) | 0.67 | 0.40 | 0.61 | 0.84 | 0.91 |
| Inventory Turnover Ratio (X) | 0.66 | 0.71 | 0.86 | 0.29 | 0.22 |
| Interest Coverage Ratio (X) | 3.08 | 2.62 | 4.20 | 6.60 | 6.57 |
| Interest Coverage Ratio (Post Tax) (X) | 1.13 | -0.22 | 1.21 | 1.57 | -2.00 |
| Enterprise Value (Cr.) | 4988.85 | 5245.26 | 3590.64 | 4151.85 | 2477.79 |
| EV / Net Operating Revenue (X) | 1.84 | 2.01 | 1.49 | 1.94 | 1.30 |
| EV / EBITDA (X) | 10.17 | 16.67 | 9.97 | 11.08 | 7.92 |
| MarketCap / Net Operating Revenue (X) | 1.26 | 1.41 | 0.81 | 1.36 | 0.89 |
| Price / BV (X) | 0.58 | 0.65 | 0.33 | 0.52 | 0.29 |
| Price / Net Operating Revenue (X) | 1.26 | 1.41 | 0.81 | 1.36 | 0.89 |
| EarningsYield | 0.00 | -0.04 | -0.01 | 0.01 | -0.09 |
After reviewing the key financial ratios for Dishman Carbogen Amcis Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has increased from -9.79 (Mar 24) to 0.21, marking an increase of 10.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has increased from -9.79 (Mar 24) to 0.21, marking an increase of 10.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has increased from 10.04 (Mar 24) to 18.94, marking an increase of 8.90.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 371.91. It has increased from 358.90 (Mar 24) to 371.91, marking an increase of 13.01.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 371.91. It has increased from 358.90 (Mar 24) to 371.91, marking an increase of 13.01.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 172.93. It has increased from 166.82 (Mar 24) to 172.93, marking an increase of 6.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 31.29. This value is within the healthy range. It has increased from 20.07 (Mar 24) to 31.29, marking an increase of 11.22.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.56. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 12.56, marking an increase of 12.32.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from -7.80 (Mar 24) to 1.23, marking an increase of 9.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has increased from -9.79 (Mar 24) to 0.20, marking an increase of 9.99.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has increased from -9.79 (Mar 24) to 0.20, marking an increase of 9.99.
- For PBDIT Margin (%), as of Mar 25, the value is 18.09. This value is within the healthy range. It has increased from 12.03 (Mar 24) to 18.09, marking an increase of 6.06.
- For PBIT Margin (%), as of Mar 25, the value is 7.26. This value is below the healthy minimum of 10. It has increased from 0.14 (Mar 24) to 7.26, marking an increase of 7.12.
- For PBT Margin (%), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 10. It has increased from -4.67 (Mar 24) to 0.71, marking an increase of 5.38.
- For Net Profit Margin (%), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has increased from -5.86 (Mar 24) to 0.11, marking an increase of 5.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 8. It has increased from -5.86 (Mar 24) to 0.11, marking an increase of 5.97.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 15. It has increased from -2.72 (Mar 24) to 0.05, marking an increase of 2.77.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 10. It has increased from 0.05 (Mar 24) to 2.43, marking an increase of 2.38.
- For Return On Assets (%), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -1.60 (Mar 24) to 0.03, marking an increase of 1.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.19, marking an increase of 0.15.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from 0.34 (Mar 24) to 0.35, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. There is no change compared to the previous period (Mar 24) which recorded 0.27.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has increased from 0.75 (Mar 24) to 1.14, marking an increase of 0.39.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.40 (Mar 24) to 0.67, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 4. It has decreased from 0.71 (Mar 24) to 0.66, marking a decrease of 0.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 3.08, marking an increase of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 3. It has increased from -0.22 (Mar 24) to 1.13, marking an increase of 1.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,988.85. It has decreased from 5,245.26 (Mar 24) to 4,988.85, marking a decrease of 256.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.84, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 25, the value is 10.17. This value is within the healthy range. It has decreased from 16.67 (Mar 24) to 10.17, marking a decrease of 6.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has decreased from 1.41 (Mar 24) to 1.26, marking a decrease of 0.15.
- For Price / BV (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 0.65 (Mar 24) to 0.58, marking a decrease of 0.07.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has decreased from 1.41 (Mar 24) to 1.26, marking a decrease of 0.15.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to 0.00, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dishman Carbogen Amcis Ltd:
- Net Profit Margin: 0.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.43% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.05% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.4 (Industry average Stock P/E: 44.14)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.35
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Dishman Corporate House, Iscon-Bopal Road, Ahmedabad Gujarat 380058 | dishman@dishmangroup.com www.imdcal.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Janmejay R Vyas | Chairman |
| Mr. Arpit J Vyas | Global Managing Director |
| Mrs. Deohooti J Vyas | Whole Time Director |
| Mr. Rajendra S Shah | Independent Director |
| Mr. Subir Kumar Das | Independent Director |
| Mr. Maitri K Mehta | Independent Director |
FAQ
What is the intrinsic value of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd's intrinsic value (as of 17 November 2025) is 27.99 which is 88.89% lower the current market price of 252.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,949 Cr. market cap, FY2025-2026 high/low of 322/178, reserves of ₹6,334 Cr, and liabilities of 11,109 Cr.
What is the Market Cap of Dishman Carbogen Amcis Ltd?
The Market Cap of Dishman Carbogen Amcis Ltd is 3,949 Cr..
What is the current Stock Price of Dishman Carbogen Amcis Ltd as on 17 November 2025?
The current stock price of Dishman Carbogen Amcis Ltd as on 17 November 2025 is 252.
What is the High / Low of Dishman Carbogen Amcis Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dishman Carbogen Amcis Ltd stocks is 322/178.
What is the Stock P/E of Dishman Carbogen Amcis Ltd?
The Stock P/E of Dishman Carbogen Amcis Ltd is 26.4.
What is the Book Value of Dishman Carbogen Amcis Ltd?
The Book Value of Dishman Carbogen Amcis Ltd is 406.
What is the Dividend Yield of Dishman Carbogen Amcis Ltd?
The Dividend Yield of Dishman Carbogen Amcis Ltd is 0.00 %.
What is the ROCE of Dishman Carbogen Amcis Ltd?
The ROCE of Dishman Carbogen Amcis Ltd is 2.42 %.
What is the ROE of Dishman Carbogen Amcis Ltd?
The ROE of Dishman Carbogen Amcis Ltd is 0.32 %.
What is the Face Value of Dishman Carbogen Amcis Ltd?
The Face Value of Dishman Carbogen Amcis Ltd is 2.00.